RAC 11.1% $1.37 race oncology ltd

General Comments / Chat, page-24

  1. 2,679 Posts.
    lightbulb Created with Sketch. 10298
    The answer is nobody really knows exactly how much was spent on Bisantrene in its former life. We do know that around 2000 patients were given Bisantrene and even at $100K per patient that works out at $200 million. This doesn’t take into account all the preclinical work that was done.

    The real value of all the past trials today is not how much was spent from the 1970s to 1990s, but how much we know about Bisantrene. To replicate this work today would probably cost you in excess of US$300 million if you could get access to the patients, which in the case of AML would be impossible.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.